Mark McKenna, Prometheus Biosciences chairman & CEO

With clear PhII win in IBD, Prometheus thwarts Pfiz­er com­par­isons as it fol­lows Hu­mi­ra 'play­book'

Prometheus Bio­sciences re­port­ed a clear Phase II win in two in­flam­ma­to­ry bow­el dis­ease con­di­tions in a clin­i­cal de­vel­op­ment race with Pfiz­er, plant­i­ng the biotech’s flag in a field of an­ti­bod­ies at­tempt­ing to go against black box-cor­nered JAK in­hibitors and Ab­b­Vie’s Hu­mi­ra.

Shares $RXDX have soared since the sum­mer — a small dip last week notwith­stand­ing when ri­val Pfiz­er teamed up with Roivant on a new com­pa­ny for their com­pet­ing an­ti-TL1A mon­o­clon­al an­ti­body. And they sky­rock­et­ed once again Wednes­day morn­ing, climb­ing from $36 apiece to more than $100 on the back of two Phase II stud­ies: one place­bo-con­trolled in ul­cer­a­tive col­i­tis and the oth­er an open-la­bel tri­al in pa­tients with Crohn’s dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.